Jones Financial Companies
ANIK icon

Jones Financial Companies’s Anika Therapeutics ANIK Stock Holding History

Jones Financial Companies’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.21K Buy
+85
New +$987 ﹤0.01% 4301
2021
Q2 		– Sell
-72
Closed -$3K – 633
2021
Q1 		$3K Buy
72
+39
+118% +$1.48K ﹤0.01% 693
2020
Q4 		$1K Buy
+33
New +$1.25K ﹤0.01% 640

Other funds holding ANIK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Jones Financial Companies's ANIK Position: Q1 2026 in Review

Jones Financial Companies opened a new position in Anika Therapeutics (ANIK) in Q1 2026: 85 shares worth $1.21K. The stake represents ﹤0.01% of the portfolio and ranks #4301 among its holdings. This is a return to the name: Jones Financial Companies previously reported a position in ANIK as recently as Q1 2021.

Jones Financial Companies first reported a position in ANIK in Q4 2020 and has held it in 3 quarters since. The position peaked at $3K in Q1 2021. 130 funds tracked by Wall St. Rank hold ANIK as of Q1 2026.

  • Jones Financial Companies held 85 shares of Anika Therapeutics worth $1.21K as of Q1 2026.
  • Anika Therapeutics was a new Jones Financial Companies position in Q1 2026.
  • Anika Therapeutics made up ﹤0.01% of Jones Financial Companies's portfolio in Q1 2026, its #4301 holding.
  • Jones Financial Companies first reported a position in Anika Therapeutics in Q4 2020 and has held it in 3 quarters since.
  • Jones Financial Companies's Anika Therapeutics position peaked at $3K in Q1 2021.
  • 130 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2026.

Based on Jones Financial Companies's 13F filing for Q1 2026, filed 15 May 2026.